483
Nanhai Beisha Pharmaceutical Co., Ltd.FDA 483 - Nanhai Beisha Pharmaceutical Co., Ltd. - September 19, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Nanhai Beisha Pharmaceutical Co., Ltd. in Nanhai, China, revealed four significant observations concerning its API manufacturing operations. The firm failed to maintain accurate and contemporaneous documentation, control written records, and establish adequate cleaning procedures for equipment. Additionally, raw materials were not stored under appropriate temperature conditions, indicating a lack of adherence to GMP requirements.
Open in Dashboard
ID · 711fde44-e52a-4976-8a30-0e76c5acf484